Medicure Inc. (OTCMKTS:MCUJF) Short Interest Down 50.5% in April

Medicure Inc. (OTCMKTS:MCUJFGet Free Report) saw a large decrease in short interest during the month of April. As of April 30th, there was short interest totaling 5,780 shares, a decrease of 50.5% from the April 15th total of 11,680 shares. Based on an average trading volume of 182 shares, the short-interest ratio is presently 31.8 days. Currently, 0.1% of the company’s stock are sold short.

Medicure Stock Performance

MCUJF opened at $0.80 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.02 and a quick ratio of 0.77. Medicure has a fifty-two week low of $0.68 and a fifty-two week high of $0.97. The firm has a market capitalization of $8.39 million, a PE ratio of -1.64 and a beta of 0.97. The company’s 50-day moving average is $0.83 and its 200 day moving average is $0.84.

Medicure (OTCMKTS:MCUJFGet Free Report) last posted its earnings results on Thursday, April 23rd. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.25). Medicure had a negative return on equity of 41.55% and a negative net margin of 24.61%.The business had revenue of $6.13 million during the quarter, compared to analyst estimates of $3.62 million.

About Medicure

(Get Free Report)

Medicure Pharmaceutical Corp. is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of therapies in the cardiovascular and critical‐care markets. The company advances its business through a combination of in-licensing, acquisitions and strategic partnerships designed to build a diversified portfolio of prescription products that address unmet medical needs.

Headquartered in Montreal, Canada, Medicure operates in North America and selectively in Europe through licensing agreements with regional distributors.

See Also

Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.